



RNA-Based Vaccines Development

Guest Editor:

Dr. Vrinda Gote

Scientist I, Viral Vaccines R&D,
Inventprise Inc., Redmond, WA,
USA

Deadline for manuscript
submissions:

25 August 2024

Message from the Guest Editor

RNA therapeutics comprise a rapidly expanding category of prophylactic and therapeutic vaccines that will speed up the progression of therapeutics to the clinic. RNA-based vaccines also have the potential to actualize personalized medicine and the ability to make the term “undruggable” obsolete. The recent developments in the upstream generation, downstream purification, and cellular delivery of RNA have enabled the development of RNA-based therapeutics for a variety of vaccines.

The main focus of this Special Issue is to critically analyze the current strategies in the field of RNA-based vaccines against both cancer and infectious disease. We are aiming to shed light on new emerging technologies as well as to illustrate the effect of vaccines. Classes of RNA-based therapeutics include aptamers, antisense oligonucleotides, microRNAs, small interfering RNAs, and messenger RNA. Additionally, articles describing the developments of nanocarriers for RNA-based vaccines are also invited. We also invite papers that describe the advantages and disadvantages of the clinical translation of prophylactic and therapeutic vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com